News/ News/ R&D Roche trumpets data for Soliris rival in NMOSD after US, EU filings Phil Taylor Alexion, rare disease, Roche, satralizumab, Soliris 0 Comment Roche has continued to build the case for satralizumab, its experimental therapy for rare disease neuromyelitis optica spectrum Share X Roche trumpets data for Soliris rival in NMOSD after US, EU filings https://pharmaphorum.com/news/roche-trumpets-data-for-soliris-rival-in-nmosd-after-us-eu-filings/
News/ News/ R&D/ Top stories Roche preps filings for satralizumab in rare disease NMOSD Phil Taylor Alexion, rare disease, Roche, satralizumab, Soliris 0 Comment Roche is two for two in its phase 3 trials programme for satralizumab in the rare disease neuromyelitis Share X Roche preps filings for satralizumab in rare disease NMOSD https://pharmaphorum.com/news/roche-preps-filings-for-satralizumab-in-rare-disease-nmosd/
Alexion, rare disease, Roche, satralizumab, Soliris
0 Comment
